Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Conditions
Lung
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is a multicohort phase 2 study to evaluate the efficacy of pembrolizumab combined with the investigational drug sitravatinib in the frontline treatment of advanced, non-squamous PD-L1 positive NSCLC.
- Trial withYale Cancer Center
- Start Date03/03/2022
- End Date02/01/2025
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Adam Boruchov, MD
- Agatha Hecht
- Andrea Brennan
- Andrea Martelli
- Anne Chiang, MD, PhD
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- Carrie Fijal, MSN, AGPCNP-BC, OCN
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Emily Collier, MD
- Emily Duffield, APRN
- Frederick Wilson, MD, PhD
- Harold Tara Jr, MD
- Henry S. Park, MD, MPH
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kathryn Medow, APRN
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- M. Sung Lee, MD
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Roy S. Herbst, MD, PhD
- Sara Anastasio, RN
- Sarah Carlson
- Scott Gettinger, MD
- Stephanie Paine, APRN
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Susan Rabinowe, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Xuanthao Thi Nguyen
- Zia Rahman, MD
- Last Updated11/11/2022
- Study HIC#2000030093